Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2025)

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting

October 29 to November 1, 2025

  1. All
  2. gMG

PDF

Assessing efficacy and safety of gefurulimab in generalised myasthenia gravis: baseline characteristics from PREVAIL

PDF

Assessing oral corticosteroid tapering in ravulizumab-treated adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: the phase 4, global OCTAGON study design

PDF

Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalised myasthenia gravis global registry

PDF

Corticosteroid toxicity and related healthcare resource utilization in patients with myasthenia gravis in the USA

PDF

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

PDF

Impact on healthcare resource utilization in early initiators of ravulizumab or efgartigimod for treatment of generalized myasthenia gravis in the USA

PDF

Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with generalized myasthenia gravis in the USA

PDF

Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal fc receptor

PDF

Outcomes for patients receiving ravulizumab or efgartigimod treatment within two years of generalized myasthenia gravis diagnosis: a retrospective subanalysis of US medical records

PDF

Phase 1 study evaluating gefurulimab pharmacokinetics and safety following delivery via autoinjector or prefilled syringe in healthy adults

PDF

Prediction of myasthenia gravis crisis events by a machine learning algorithm

HTML

Predictors of myasthenia gravis hospitalizations in the PREDICT study

HTML

Retrospective analysis of efgartigimod alfa-fcab or efgartigimod alfa and hyaluronidase-qvfc switches to ravulizumab in patients with myasthenia gravis

HTML

Retrospective analysis of intravenous immunoglobulin (IVIg) infusion switches to ravulizumab (Ultomiris) in patients with myasthenia gravis

PDF

Usability of gefurulimab autoinjector (AI) and prefilled syringe (PFS) devices: a human factors (HF) validation study

PDF

Characterization of antibiotic prophylaxis risk mitigation practices across eculizumab and ravulizumab phase 3 clinical trials in adults with PNH, aHUS, gMG, and NMOSD

PDF

Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder: an updated analysis of US clinical practice

PDF

Assessing efficacy and safety of gefurulimab in generalised myasthenia gravis: baseline characteristics from PREVAIL

PDF

Assessing oral corticosteroid tapering in ravulizumab-treated adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: the phase 4, global OCTAGON study design

PDF

Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalised myasthenia gravis global registry

PDF

Corticosteroid toxicity and related healthcare resource utilization in patients with myasthenia gravis in the USA

PDF

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

PDF

Impact on healthcare resource utilization in early initiators of ravulizumab or efgartigimod for treatment of generalized myasthenia gravis in the USA

PDF

Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with generalized myasthenia gravis in the USA

PDF

Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal fc receptor

PDF

Outcomes for patients receiving ravulizumab or efgartigimod treatment within two years of generalized myasthenia gravis diagnosis: a retrospective subanalysis of US medical records

PDF

Phase 1 study evaluating gefurulimab pharmacokinetics and safety following delivery via autoinjector or prefilled syringe in healthy adults

PDF

Prediction of myasthenia gravis crisis events by a machine learning algorithm

HTML

Predictors of myasthenia gravis hospitalizations in the PREDICT study

HTML

Retrospective analysis of efgartigimod alfa-fcab or efgartigimod alfa and hyaluronidase-qvfc switches to ravulizumab in patients with myasthenia gravis

HTML

Retrospective analysis of intravenous immunoglobulin (IVIg) infusion switches to ravulizumab (Ultomiris) in patients with myasthenia gravis

PDF

Usability of gefurulimab autoinjector (AI) and prefilled syringe (PFS) devices: a human factors (HF) validation study

PDF

Characterization of antibiotic prophylaxis risk mitigation practices across eculizumab and ravulizumab phase 3 clinical trials in adults with PNH, aHUS, gMG, and NMOSD

PDF

Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder: an updated analysis of US clinical practice

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States